← Back to Screener
Pasithea Therapeutics Corp. Common Stock (KTTA)
Price$0.72
Favorite Metrics
Price vs S&P 500 (26W)-9.68%
Price vs S&P 500 (4W)-16.34%
Market Capitalization$18.52M
All Metrics
Book Value / Share (Quarterly)$2.39
P/TBV (Annual)0.53x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.66
Price vs S&P 500 (YTD)-46.59%
Gross Margin (TTM)100.54%
Net Profit Margin (TTM)-6478.41%
EPS (TTM)$-3.47
10-Day Avg Trading Volume0.54M
EPS Excl Extra (TTM)$-3.47
EPS (Annual)$-13.01
ROI (Annual)-68.22%
Gross Margin (Annual)-14.57%
Cash / Share (Quarterly)$2.39
ROA (Last FY)-61.12%
Revenue Growth TTM (YoY)740.47%
EBITD / Share (TTM)$-2.90
Operating Margin (TTM)-7032.69%
Cash Flow / Share (Annual)$-9.99
P/B Ratio0.34x
P/B Ratio (Quarterly)0.54x
Net Income / Employee (Annual)$-4
Net Interest Coverage (TTM)-4346.00x
ROA (TTM)-77.42%
EPS Incl Extra (Annual)$-13.01
Current Ratio (Annual)6.58x
Quick Ratio (Quarterly)11.19x
3-Month Avg Trading Volume0.36M
52-Week Price Return-45.81%
Revenue / Employee (TTM)$16,047
Tangible BV / Share (Quarterly)$2.23
P/S Ratio (Annual)1226.19x
Asset Turnover (Annual)0.00x
52-Week High$3.79
EPS Excl Extra (Annual)$-13.01
26-Week Price Return-0.93%
Quick Ratio (Annual)6.31x
13-Week Price Return-15.64%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.35x
Enterprise Value$-36.644
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-14394.04%
Cash / Share (Annual)$4.97
3-Month Return Std Dev59.33%
Net Income / Employee (TTM)$-5
ROE (Last FY)-68.22%
Net Interest Coverage (Annual)-121163.20x
EPS Basic Excl Extra (Annual)$-13.01
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.47
ROI (TTM)-85.49%
P/S Ratio (TTM)26.84x
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$5.36
Price vs S&P 500 (52W)-80.91%
Year-to-Date Return-42.45%
5-Day Price Return-1.67%
EPS Normalized (Annual)$-13.01
Net Profit Margin (Annual)-14394.04%
Month-to-Date Return0.08%
Cash Flow / Share (TTM)$-0.60
EBITD / Share (Annual)$-12.97
Operating Margin (Annual)-29850.33%
EPS Basic Excl Extra (TTM)$-3.47
P/TBV (Quarterly)0.58x
P/B Ratio (Annual)0.27x
Pretax Margin (TTM)-6478.41%
Book Value / Share (Annual)$10.60
Price vs S&P 500 (13W)-18.50%
Beta0.24x
Revenue / Share (TTM)$0.01
ROE (TTM)-85.49%
52-Week Low$0.28
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KTTAPasithea Therapeutics Corp. Common Stock | 26.84x | 740.47% | 100.54% | — | $0.72 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.71 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Pasithea Therapeutics is a biotechnology company developing treatments for central nervous system disorders and genetic diseases, including neurofibromatosis type 1, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, and RASopathies. Its pipeline includes PAS-004, a MEK1/2 inhibitor; PAS-003, a monoclonal antibody; and PAS-001, a small molecule therapeutic. The company leverages expertise in neuroscience and translational medicine to address significant unmet medical needs.